T Uher1,2, D Horakova1, T Kalincik3,4, N Bergsland2,5, M Tyblova1, D P Ramasamy2, Z Seidl6, M Vaneckova6, J Krasensky6, E Havrdova1, R Zivadinov2,7. 1. Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic. 2. Department of Neurology, Buffalo Neuroimaging Analysis Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA. 3. Department of Medicine, Melbourne Brain Centre, University of Melbourne, Melbourne, Australia. 4. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. 5. IRCCS 'S. Maria Nascente', Don Gnocchi Foundation, Milan, Italy. 6. Department of Radiology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. 7. MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
Abstract
BACKGROUND AND PURPOSE: Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β-1a. In a prospective observational study, the predictive role of baseline and 6-month changes in magnetic resonance imaging outcomes was investigated with respect to relapse activity and development of confirmed disability progression in patients after 48 months. METHODS: This study examined 210 patients. Multivariate Cox proportional hazard models were used to analyse predictors of relapse activity and confirmed disability progression after 48 months. RESULTS: Greater T2 lesion volume [hazard ratio (HR) 1.81; P = 0.005] and the presence of contrast-enhancing lesions (HR 2.13; P < 0.001) at baseline were significantly associated with increased cumulative risk of a second clinical attack over 48 months. A greater decrease of the corpus callosum volume (HR 2.74; P = 0.001) and greater lateral ventricle volume enlargement (HR 2.43; P = 0.002) at 6 months relative to baseline were associated with increased cumulative risk of a second clinical attack between months 6 and 48. In addition, increased risk of confirmed disability progression over 48 months in patients with greater lateral ventricle volume enlargement between baseline and 6 months (HR 4.70; P = 0.001) was detected. CONCLUSIONS: A greater T2 lesion volume, the presence of contrast-enhancing lesions at baseline, decrease of corpus callosum volume and lateral ventricle volume enlargement over the first 6 months in patients after the first demyelinating event treated with weekly intramuscular interferon β-1a may assist in identification of patients with the highest risk of a second clinical attack and progression of disability.
BACKGROUND AND PURPOSE: Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β-1a. In a prospective observational study, the predictive role of baseline and 6-month changes in magnetic resonance imaging outcomes was investigated with respect to relapse activity and development of confirmed disability progression in patients after 48 months. METHODS: This study examined 210 patients. Multivariate Cox proportional hazard models were used to analyse predictors of relapse activity and confirmed disability progression after 48 months. RESULTS: Greater T2 lesion volume [hazard ratio (HR) 1.81; P = 0.005] and the presence of contrast-enhancing lesions (HR 2.13; P < 0.001) at baseline were significantly associated with increased cumulative risk of a second clinical attack over 48 months. A greater decrease of the corpus callosum volume (HR 2.74; P = 0.001) and greater lateral ventricle volume enlargement (HR 2.43; P = 0.002) at 6 months relative to baseline were associated with increased cumulative risk of a second clinical attack between months 6 and 48. In addition, increased risk of confirmed disability progression over 48 months in patients with greater lateral ventricle volume enlargement between baseline and 6 months (HR 4.70; P = 0.001) was detected. CONCLUSIONS: A greater T2 lesion volume, the presence of contrast-enhancing lesions at baseline, decrease of corpus callosum volume and lateral ventricle volume enlargement over the first 6 months in patients after the first demyelinating event treated with weekly intramuscular interferon β-1a may assist in identification of patients with the highest risk of a second clinical attack and progression of disability.
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; D P Ramasamy; D Hojnacki; A A Lizarraga; C Kolb; S Eckert; B Weinstock-Guttman; R Zivadinov Journal: AJNR Am J Neuroradiol Date: 2020-08-06 Impact factor: 3.825
Authors: Michael G Dwyer; Diego Silva; Niels Bergsland; Dana Horakova; Deepa Ramasamy; Jaqueline Durfee; Manuela Vaneckova; Eva Havrdova; Robert Zivadinov Journal: Neuroimage Clin Date: 2017-06-19 Impact factor: 4.881
Authors: Tomas Uher; Sabine Schaedelin; Barbora Srpova; Christian Barro; Niels Bergsland; Michael Dwyer; Michaela Tyblova; Karolina Vodehnalova; Pascal Benkert; Johanna Oechtering; David Leppert; Yvonne Naegelin; Jan Krasensky; Manuela Vaneckova; Eva Kubala Havrdova; Ludwig Kappos; Robert Zivadinov; Dana Horakova; Jens Kuhle; Tomas Kalincik Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-04-09
Authors: Johanna von Gumberz; Mina Mahmoudi; Kim Young; Sven Schippling; Roland Martin; Christoph Heesen; Susanne Siemonsen; Jan-Patrick Stellmann Journal: PeerJ Date: 2016-09-20 Impact factor: 2.984